Koselugo (selumetinib)
- Region
- 🇪🇺 EU
- Active substance
- selumetinib
- Company
- AstraZeneca AB
- Status
- Authorised
- Therapeutic area
- Neurofibromatosis 1
- CHMP opinion
- Thu 22 Apr 2021
- EU approval
- Thu 17 Jun 2021
- Designations
- Orphan, Conditional, Additional monitoring
- Application
- EMEA/H/C/005244
- ATC
- L01EE04
- Official record
- www.ema.europa.eu
Indication
Koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adult and paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and older. Koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in patients with neurofibromatosis type 1 (NF1) aged 1 year to less than 7 years and for older patients with swallowing difficulties.
Regulatory milestones
No milestones recorded in the last year.
Follow Koselugo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.